IQVIA and Flagship Pioneering Collaborate to Accelerate Breakthrough Life Sciences Companies

IQVIA and Flagship Pioneering have announced a strategic collaboration to accelerate the development of breakthrough life sciences companies. The collaboration will provide access to IQVIA's comprehensive capabilities, including information assets, analytics, and domain expertise across the drug development life cycle. The collaboration will focus on three service areas: drug development strategy and analytics, clinical development, and asset valuation and due diligence. The partnership aims to foster the development of emerging biopharma companies and advance the development of life-saving therapies.

IQVIA (NYSE: IQV) and Flagship Pioneering have announced a strategic collaboration aimed at accelerating the development of breakthrough life sciences companies. The partnership, announced on August 28, 2025, will leverage IQVIA's comprehensive capabilities in information assets, analytics, and domain expertise to support Flagship's ecosystem of biopharma companies throughout the drug development life cycle.

The collaboration will focus on three key service areas: drug development strategy and analytics, clinical development, and asset valuation and due diligence. By combining IQVIA's cutting-edge technologies in artificial intelligence, analytics, and clinical trial design and execution with Flagship's pioneering bioplatforms, the partnership aims to create a more seamless, efficient, and effective approach to drug development and early commercial viability.

Rob Kotchie, president of Real World Solutions at IQVIA, stated, "Working with Flagship Pioneering to foster the development of emerging biopharma companies that will advance the development of life-saving therapies fits squarely within IQVIA's mission to accelerate innovations for a healthier world and bring better treatments to patients faster." [1]

David Khougazian, executive partner at Flagship Pioneering, added, "This collaboration brings enormous value to our platform companies by providing them the potential to greatly expand their reach and impact. By using IQVIA's robust data infrastructure and analytics capabilities alongside Flagship's pioneering bioplatforms, this collaboration is poised to positively impact the ability of our companies to accelerate their platform capabilities and drive value creation for life sciences." [2]

IQVIA, a global leader in clinical research services, commercial insights, and healthcare intelligence, will provide its extensive expertise and technology to Flagship's portfolio of over 40 companies. Flagship Pioneering, with $14 billion in assets under management, has a track record of originating and fostering scientific ventures, resulting in over $60 billion in aggregate value since its launch in 2000. [3]

The collaboration comes as IQVIA resolves a long-standing feud with Veeva Systems, forging a long-term partnership. This strategic move by IQVIA signals a commitment to supporting the biotech industry's innovative efforts, particularly those spearheaded by Flagship Pioneering. [3]

References:
[1] https://www.prnewswire.com/news-releases/iqvia-and-flagship-pioneering-announce-strategic-collaboration-to-accelerate-the-development-of-breakthrough-life-sciences-companies-302540186.html
[2] https://www.marketscreener.com/news/iqvia-and-flagship-pioneering-announce-strategic-collaboration-to-accelerate-development-of-breakthr-ce7c50dfd08af126
[3] https://www.fiercebiotech.com/biotech/flagship-pioneering-taps-iqvia-biotech-support-company-fleet